Public Sector Pension Investment Board Boosts Position in Certara, Inc. $CERT

Public Sector Pension Investment Board raised its stake in Certara, Inc. (NASDAQ:CERT) by 24.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 469,910 shares of the company’s stock after purchasing an additional 93,810 shares during the period. Public Sector Pension Investment Board owned 0.29% of Certara worth $5,742,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new position in shares of Certara in the 1st quarter valued at $259,000. Goldman Sachs Group Inc. lifted its position in Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after acquiring an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Certara by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after acquiring an additional 35,954 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Certara by 25.3% during the second quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock worth $66,391,000 after purchasing an additional 1,145,554 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wall Street Zen cut Certara from a “buy” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Stephens lowered their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, December 12th. KeyCorp cut their target price on shares of Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, January 8th. Finally, BMO Capital Markets assumed coverage on shares of Certara in a research note on Thursday, November 13th. They set a “market perform” rating and a $9.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.82.

Certara Stock Performance

Shares of CERT opened at $6.53 on Thursday. The stock has a market capitalization of $1.04 billion, a P/E ratio of 93.29 and a beta of 1.47. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09. Certara, Inc. has a 1 year low of $6.44 and a 1 year high of $15.38. The company’s fifty day moving average is $8.66 and its two-hundred day moving average is $10.07.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.